Your browser doesn't support javascript.
loading
Health Care Utilization and Clinical Management of All-Cause and Norovirus-Associated Acute Gastroenteritis Within a US Integrated Health Care System.
Cates, Jordan; Mattison, Claire P; Groom, Holly; Donald, Judy; Hall, Rebecca P; Schmidt, Mark A; Hall, Aron J; Naleway, Allison L; Mirza, Sara A.
Afiliação
  • Cates J; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Mattison CP; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Groom H; Cherokee Nation Operational Solutions, Tulsa, Oklahoma, USA.
  • Donald J; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
  • Hall RP; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
  • Schmidt MA; Emory University Hospital Midtown, Atlanta, Georgia, USA.
  • Hall AJ; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
  • Naleway AL; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Mirza SA; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
Open Forum Infect Dis ; 11(4): ofae151, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38628950
ABSTRACT

Background:

Norovirus-associated acute gastroenteritis (AGE) exacts a substantial disease burden, yet the health care utilization for and clinical management of norovirus-associated AGE are not well characterized.

Methods:

We describe the health care encounters and therapeutics used for patients with all-cause and norovirus-associated AGE in the Kaiser Permanente Northwest health system from 1 April 2014 through 30 September 2016. Medical encounters for patients with AGE were extracted from electronic health records, and encounters within 30 days of one another were grouped into single episodes. An age-stratified random sample of patients completed surveys and provided stool samples for norovirus testing.

Results:

In total, 40 348 individuals had 52 509 AGE episodes; 460 (14%) of 3310 participants in the substudy tested positive for norovirus. An overall 35% of all-cause AGE episodes and 29% of norovirus-associated AGE episodes had ≥2 encounters. While 80% of norovirus-associated AGE episodes had at least 1 encounter in the outpatient setting, all levels of the health care system were affected 10%, 22%, 10%, and 2% of norovirus-associated AGE episodes had at least 1 encounter in virtual, urgent care, emergency department, and inpatient settings, respectively. Corresponding proportions of therapeutic use between norovirus-positive and norovirus-negative episodes were 13% and 10% for intravenous hydration (P = .07), 65% and 50% for oral rehydration (P < .001), 7% and 14% for empiric antibiotic therapy (P < .001), and 33% and 18% for antiemetics (P < .001).

Conclusions:

Increased health care utilization and therapeutics are likely needed for norovirus-associated AGE episodes during peak norovirus winter seasons, and these data illustrate that effective norovirus vaccines will likely result in less health care utilization.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos